SLC5A2 and type 2 diabetes mellitus: The glucose-independent findings regarding SGLT2 inhibition align with the recent findings of the CREDENCE [283] and CANVAS [284] studies, which established that the SGLT2 inhibitor canagliflozin provided renoprotection in patients with low eGFR and proteinuria, even with minimal glucose-lowering effects in individuals with type 2 diabetes.